辛伐他汀治疗慢性阻塞性肺疾病的效果及对患者BNP的影响

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo research the curative effect of Simvastatin treatment for chronic obstructive pulmonary disease and its effects on patients with plasma brain natriuretic peptide.Methods180 cases of chronic obstructive pulmonary disease patients were selected as the research object,in the department of respiratory medicine,from October 2015 to April 2016.They were randomly divided into control group and treatment group,90 cases in each group.Two groups of patients were treated with routine,Simvastatin treatment group patients were used;eight months after treatment,two groups of patients were compared before and after treatment in patients with lung function index,dyspnea score index,plasma BNP levels.ResultsAfter 8 months of treatment,two groups of patients with FEV1%and FEV1/FVC levels were significantly better than before treatment （P<0.05）;treatment group patients were found to breathing difficulties questionnaire（mMRC） assessment level was significantly reduced,and the patients in treatment group were found based dyspnea index （BDI） score compared with the control group with significant difference（P<0.05）;treatment group patients were found the BNP level was significantly reduced （P<0.05）.ConclusionSimvastatin combined with routine treatment of chronic obstructive pulmonary disease patients to improve patients′lung function and respiratory difficulty score,can reduce patients BNP,worth clinical promotion.

Key words： Simvastatin Chronic obstructive pulmonary disease Clinical effect Brain natriuretic peptide

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHENG Guang-yang
	FAN Rong－xing
	LIANG Da－qiang
	FENG Jun－xing
	DENG Jin－xia

Cite this article:

ZHENG Guang-yang,FAN Rong－xing,LIANG Da－qiang, et al. The effect of Simvastatin treatment of chronic obstructive pulmonary disease（COPD）and its influence on patients with BNP paribas[J]. 中国当代医药, 2017, 24(16): 45-47.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I16/45

[1]	庞红燕.2016年更新版GOLD慢性阻塞性肺疾病诊断、治疗和预防的全球策略简介[J].中国医学前沿杂志（电子版），2016，8（7）：30-34.
[2]	Global initiative for chronic obstructive lung disease.Global strategy for the diagnosis，management，and prevention of chronic obstructive pulmonary disease 2017 report[EB/OL].（2016-11-16）[2016-12-09].http://www.goldcopd.org.
[3]	陈焕珍.辛伐他汀对老年慢性阻塞性肺疾病患者肺功能、免疫功能及生活质量的影响[J].临床肺科杂志，2016，21（5）：940-942.
[4]	刘瑞琪.他汀类药物治疗AECOPD的临床研究[J].实用药物与临床，2015，18（6）：745-747.
[5]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南（2013年修订版）[J].中华结核和呼吸杂志，2013，36（4）：255-264.
[6]	葛均波，徐永健.内科学8版[M].北京：人民卫生出版社，2014：24.
[7]	李艳娇.无支撑上肢锻炼对慢性阻塞性肺疾病患者的康复效果[J].中国康复理论与实践，2016，22（6）：719-723.
[8]	Barnes PJ.Inflammatory mechanisms in patients with chronic obstructive pulmonary disease[J].J Allergy Clin Immunol，2016，138（1）：16-27.
[9]	吴艳.血清NT-proBNP、D-二聚体及血气分析与老年慢性阻塞性肺疾病急性加重合并肺动脉高压患者的相关性[J].中国老年学杂志，2015，13（19）：5550-5551.
[10]	干丽萍，陈建建，张秋，等.血浆NT-proBNP对慢性阻塞性肺疾病急性加重期患者预后的预测价值[J].实用医学杂志，2015，31（7）：1166-1168.
[11]	董煜.COPD急性加重期患者的hs-CRP、PCT和BNP水平的变化及临床诊断价值分析[J].西北国防医学杂志，2016，37（9）：599-601.
[12]	童旭芳.辛伐他汀对慢性阻塞性肺疾病炎症因子的影响[J].江西医药，2015，50（5）：434-435.
[13]	李晓光.阿奇霉素联合辛伐他汀对慢性阻塞性肺疾病合并肺动脉高压的治疗效果观察[J].中国医药指南，2017，15（1）：41-42.
[14]	李玉明，刘若琳，高磊，等.综合康复治疗对老年慢性阻塞性肺疾病患者肺功能和运动耐力的影响[J].中华老年医学杂志，2014，33（7）：737-740.
[15]	刘茜，王喜春，甘丹，等.辛伐他汀对老年COPD合并PAH患者VEGF水平及肺功能的影响[J].重庆医学，2015，44（6）：761-762.